enVVeno Medical Corporation

NasdaqCM NVNO

enVVeno Medical Corporation Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 39.43 M

enVVeno Medical Corporation Net Cash Used Provided By Financing Activities is USD 39.43 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

enVVeno Medical Corporation Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.00, a 100.00% change year over year.
enVVeno Medical Corporation Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -5.05 K, a -100.01% change year over year.
enVVeno Medical Corporation Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 63.96 M, a 632.80% change year over year.
enVVeno Medical Corporation Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 8.73 M, a 177.50% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqCM: NVNO

enVVeno Medical Corporation

CEO	Mr. Robert A. Berman
IPO Date	May 31, 2018
Location	United States
Headquarters	70 Doppler
Employees	31
Sector	Health Care
Industries Biotechnology Medical Instruments Pharmaceuticals

Description

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Key trends

Past 5 years